All In Biotech

Drug Trial Radar · NCT07294508

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

An Open-Label, Randomized, Multicenter, Phase II/III Clinical Study to Evaluate HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With HLX87 (HER2 ADC) as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 706 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

706

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Jan 15, 2028

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Dec 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Conditions

  • HER2 + Breast Cancer

Interventions

  • HLX87 + HLX22Drug

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .

  • HLX87 + PertuzumabDrug

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan

  • T-Dxd + PertuzumabDrug

    T-Dxd is a HER2-targeted ADC

  • THPDrug

    Pertuzumab+ Trastuzumab+Docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) (assessed by the blinded independent central review [BICR] as per RECIST v1.1)Time frame: up to 26 months
  2. Progression-free survival (PFS) (assessed by BICR as per RECIST v1.1)Time frame: up to 37 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.